Report Highlights

U.S. Collagen Supplements: Market Overview

The U.S. collagen supplements market reached $2.1 billion in 2024, driven by sustained consumer demand for functional nutrition products targeting skin elasticity, joint mobility, and bone density. The market is structured around three dominant product formats — hydrolyzed collagen peptide powders, encapsulated supplements, and ready-to-drink formats — with powders commanding the largest share due to versatility and high dosage delivery. Retail channels including Walmart, Target, and Amazon account for the majority of revenue, while direct-to-consumer brands such as Vital Proteins and Ancient Nutrition have built significant subscription-based revenue streams that insulate them from retail margin pressure.

Government agencies have shaped this market primarily through enforcement rather than promotion. The FDA regulates collagen supplements under the Dietary Supplement Health and Education Act of 1994 (DSHEA), which does not require pre-market approval but mandates good manufacturing practice (GMP) compliance under 21 CFR Part 111. The FTC governs advertising claims and has expanded its scrutiny of collagen-specific efficacy marketing since 2022. Private sector investment has led product innovation — particularly in marine-sourced and vegan-alternative collagen boosters — while the regulatory framework has constrained claim specificity, preventing direct disease-treatment language across all branded SKUs.

Policy-Driven Growth in Collagen Supplements

Three specific policy mechanisms are generating measurable demand pressure in this market. First, the FDA's enforcement of 21 CFR Part 111 GMP standards has accelerated consolidation among contract manufacturers, with compliant facilities gaining preferential access to major retail buyers who require third-party GMP audits as a condition of listing. This has raised minimum compliance investment thresholds, driving smaller brands to source from certified co-manufacturers and pushing average product costs upward by an estimated 8–12%. Second, the FTC's Health Products Compliance Guidance, updated in December 2022, requires that structure/function claims for dietary supplements be supported by competent and reliable scientific evidence, compelling brands to fund clinical substantiation studies that simultaneously serve as marketing assets and regulatory shields.

Third, the National Institutes of Health's National Center for Complementary and Integrative Health (NCCIH) has funded clinical trials examining collagen peptide efficacy for osteoarthritis and skin aging, with results published in peer-reviewed journals between 2021 and 2024. While NCCIH funding does not directly subsidize commercial products, its published findings provide the evidentiary baseline that FTC-compliant brands reference in substantiation files, effectively lowering the cost of claim defense for brands aligned with the NIH research agenda. This policy-research nexus translates into a market advantage for brands that monitor NCCIH grant outputs and reformulate products to match studied ingredient profiles and dosage ranges.

Regulatory Barriers and Compliance Costs

The primary regulatory barrier in the U.S. collagen supplements market is GMP compliance under 21 CFR Part 111, administered by the FDA's Office of Dietary Supplement Programs (ODSP). An FDA facility inspection for a mid-size collagen manufacturer typically takes 3–5 days and results in a Form 483 observation list; unresolved observations can escalate to Warning Letters that trigger retailer delisting. For brands operating their own manufacturing, achieving and maintaining GMP certification costs an estimated $250,000–$600,000 annually in infrastructure, documentation, and personnel, a barrier that effectively forces sub-scale brands into contract manufacturing arrangements where they cede formulation control and face supply chain concentration risk.

A secondary barrier is the FTC's substantiation standard for advertising claims. Under the FTC Act, Section 5, collagen brands making efficacy claims in digital advertising must maintain a substantiation file prior to publishing claims — not after a challenge is received. Legal preparation of a defensible substantiation file, including commissioned clinical trials or meta-analysis reviews, costs between $80,000 and $400,000 depending on claim specificity. Additionally, California's Proposition 65, administered by the Office of Environmental Health Hazard Assessment (OEHHA), requires heavy metal warnings on collagen products exceeding established safe harbor thresholds for lead, cadmium, and arsenic — a particular concern for marine-sourced collagen derived from fish bones, where contamination variability is highest.

Policy-Created Opportunities in U.S. Collagen Supplements

The most immediate policy-created opportunity lies in the FDA's increased scrutiny of collagen product labeling and the resulting market gap for certified, claim-compliant brands. As the ODSP intensifies GMP audits under its 2023–2027 Dietary Supplement Strategic Plan, retailers including Costco and CVS Health have implemented their own supplier qualification programmes requiring demonstrated GMP certification and third-party lab testing. Brands that achieve NSF International's NSF/ANSI 173 certification or USP Verified status gain immediate preferential access to these high-volume channels, translating certification investment into disproportionate shelf placement at scale.

A second opportunity emerges from the Department of Veterans Affairs (VA) formulary expansion for dietary supplements, which since 2021 has included select collagen-based products for veterans managing musculoskeletal conditions under the VA's Whole Health Programme. Suppliers that meet the VA's Federal Supply Schedule (FSS) qualification requirements gain access to a price-insulated institutional procurement channel entirely separate from competitive retail. Separately, proposed amendments to the Dietary Supplement Listing Act, which would mandate product listing with the FDA before market entry, create a first-mover advantage for brands already maintaining comprehensive ingredient disclosure practices — positioning them to convert compliance infrastructure into a regulatory moat as mandatory listing approaches.

Market at a Glance

Leading Market Participants

• Vital Proteins
• NeoCell (Nutraceutix)
• Ancient Nutrition
• Rousselot
• Herbalife Nutrition
• Garden of Life
• Sports Research Corporation
• Further Food
• Great Lakes Wellness
• Amandean

Regulatory and Policy Environment

The foundational legislation governing U.S. collagen supplements is the Dietary Supplement Health and Education Act of 1994 (DSHEA), which classifies collagen supplements as dietary supplements exempt from pre-market FDA approval but subject to post-market safety enforcement and GMP compliance. The FDA's Office of Dietary Supplement Programs is the primary enforcement body, with authority to issue Warning Letters, mandate recalls, and pursue injunctive relief for non-compliant manufacturers. The 21 CFR Part 111 GMP rule requires identity testing of every ingredient lot, finished product testing, and documented batch records — obligations that, when audited, reveal widespread non-compliance among smaller brands. The FDA's 2023–2027 Dietary Supplement Strategic Plan explicitly prioritizes expanding GMP surveillance inspections, signaling increased enforcement frequency through 2027.

Compared to regional peers, the U.S. framework is notably more permissive than Canada's Natural Health Products Regulations, which require pre-market product licensing through Health Canada before a collagen supplement can be sold commercially. The European Food Safety Authority (EFSA) further restricts collagen health claims, rejecting most skin and joint benefit claims for lack of specific causal evidence. This regulatory divergence makes the U.S. the most commercially attractive market for collagen innovation but also the most litigation-exposed, as the FTC's civil penalty authority under the 2021 amended consent order framework now permits fines of up to $50,120 per violation per day for deceptive health advertising — a material financial risk that underscores the compliance investment imperative for all market participants.

Long-Term Policy Outlook for U.S. Collagen Supplements

By 2028, mandatory product listing under a revised version of the Dietary Supplement Listing Act is the most consequential regulatory development anticipated for this market. The legislation, which has bipartisan Senate sponsorship and FDA administrative support, would require all dietary supplement brands — including collagen products — to register product formulations with the FDA before commercial sale, creating a de facto pre-market notification system within DSHEA's existing framework. This will raise the cost and timeline of new product launches, favour established brands with existing regulatory infrastructure, and generate a documented FDA product database that will enable more targeted enforcement against non-compliant operators through 2032.

The FTC is also expected to issue revised Health Claims Substantiation Guidelines specific to nutricosmetic products — a category that encompasses collagen supplements marketed for skin appearance — by 2026, following its 2024 request for public comment on cosmetic-adjacent supplement advertising. These guidelines will likely require randomized controlled trial evidence for skin-specific claims, eliminating observational study citations as sufficient substantiation. Brands that invest now in double-blind clinical trials for their specific collagen formulations will hold a durable regulatory asset; those relying on third-party ingredient supplier studies will face mandatory claim reformulation, disrupting brand identity and digital advertising infrastructure at scale.